3B

3B Blackbio DX Ltd

Q1 FY27Healthcare Services

3B Blackbio DX Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

3B Blackbio DX Ltd Q1 FY27 key numbers

Revenue
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. 60.5%.

As stated in 3B Blackbio DX Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on 3B Blackbio DX Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,406
Market cap₹1.1K Cr
P/E20.4

The short version

Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Q1 2026-27 Consolidated EBITDA: ₹1,466.54 Lakh, down from ₹1,619.43 Lakh in Q1 2025-26 (includes Coris' negative EBITDA of ₹(352.24) Lakh).

From 3B Blackbio DX Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. 60.5%.
  • Export sales in Q1 2026-27: ₹596.28 Lakh vs ₹430.90 Lakh in Q1 2025-26 — 38% growth.
  • 3B Standalone Q1 sales grew by 19%.
  • MDx Division revenue (excluding Coris): ₹2,342.90 Lakh vs ₹1,996.06 Lakh — about 17.4% growth.
  • Coris Q1 2026-27 revenue: €796K (~₹862.83 Lakh), slight increase vs previous year.
  • Sales model projection: Contractual/Reagent rental expected to contribute 20%-25% of total revenue long term.

2 more points from 3B Blackbio DX Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company is currently operating at ~65% installed capacity, with potential to scale to 100% during seasonal spikes; lean season utilization is ~50%, allowing flexibility. (Page 45)
  • Funds will be deployed partly in the joint venture in Manchester, UK, as needed. (Page 45)
  • (Pages 29, 45)
  • Existing & utilized capacity is implied to support growth without immediate expansion. (Page 45)

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Coris BioConcept SRL received a HAT order of EUR 1.41M to be supplied in Q3, December 2026 (Page 29).
  • The company had a Belgium Government Order for HAT valued at EUR 6.0M received in February 2024 to be supplied over 4 years (Page 29).
  • The Middle East market shows strong order inflow reflecting growing traction (Page 24).

2 more points from 3B Blackbio DX Ltd's call on order book

Create a free account to keep reading this call

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2024Q2 FY25
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Aatmaj Health (Q1 FY27)

    Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again

  • Asarfi Hospital (Q1 FY27)

    Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q

  • KMC Speciality (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • Thyrocare Technologies (Q1 FY27)

    Pathology business grew ~27%; franchisee business grew ~23-27% YoY, reflecting strong volume growth. Key concall takeaways from Thyrocare Technologies Ltd's Q1…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q1 FY27 results?

Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Q1 2026-27 Consolidated EBITDA: ₹1,466.54 Lakh, down from ₹1,619.43 Lakh in Q1 2025-26 (includes Coris' negative EBITDA of ₹(352.24) Lakh).

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company is currently operating at ~65% installed capacity, with potential to scale to 100% during seasonal spikes; lean season utilization is ~50%, allowing flexibility.

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.